Biosimilars and brand switching
What a biosimilar is, why the NHS uses them, whether switching brand is safe, and what might feel different
In short
- Biologics are made by living cells, so no two makers' versions can be exactly identical. Close versions of the original are called biosimilars.
- Biosimilars must meet strict standards showing no meaningful difference in quality, safety or effectiveness from the original.
- Infliximab, adalimumab and ustekinumab all have biosimilars in the UK.
- The UK medicines regulator says switching between the original and its biosimilars is now acceptable practice. Crohn's & Colitis UK says there is no evidence it makes Crohn's flare.
- A new brand may mean a different pen, different delivery company or slightly different ingredients. Tell your IBD team if anything changes after a switch.
On this page
What is a biosimilar?
Biologic medicines such as infliximab and adalimumab are made by living cells, and each manufacturer uses its own cells and process. Crohn's & Colitis UK explains that this means versions from different makers can never be exactly the same. The first version of a biologic is called the originator. Later versions of the same medicine from other companies are called biosimilars.12
NHS England defines a biosimilar as a biologic that has been shown to have no clinically meaningful difference from the originator in quality, safety and effectiveness. Crohn's & Colitis UK says biosimilars are thoroughly tested and have to meet strict standards before they can be used.123
This is different from ordinary chemical medicines, where several companies can make the same active ingredient and sell it under different brand names. Because biologics are large, complex molecules made by living cells, a biosimilar's active ingredient is always very close to the original but not a perfect copy, and other ingredients such as preservatives may differ.12
Which Crohn's medicines have biosimilars?
- Infliximab: Remicade was the original. Flixabi, Inflectra, Remsima and Zessly are biosimilars. Remsima also comes as an injection under the skin.
- Adalimumab: Humira was the original. Amgevita, Hyrimoz, Idacio, Imraldi and Yuflyma are biosimilars.
- Ustekinumab: Stelara was the original. Crohn's & Colitis UK lists biosimilars including Imuldosa, Otulfi, Pyzchiva, Steqeyma, Usymro, Uzpruvo, Wezenla and Yesintek.456
Your medicine is prescribed by brand name, so it is worth knowing which one you are on. Crohn's & Colitis UK says which brand you get makes no difference to how well your treatment works. You can still ask your team which one you are on.456
Do biosimilars work as well?
The evidence and the regulators say yes. A Cochrane review of infliximab for Crohn's found there may be little or no difference between the original and a biosimilar called CT-P13 in remission, response or people stopping because of side effects at six weeks, although the evidence was rated low certainty.7
NHS England says that where NICE has recommended an original biologic, the same guidance normally applies to its biosimilars. That means the NICE appraisal for infliximab and adalimumab also covers their biosimilar versions.38
Why does the NHS use them?
Biologics are one of the biggest and fastest-growing costs in the NHS medicines budget. NHS England says biosimilars are usually much cheaper than the originals, and the competition they bring lets more patients get treatment without compromising care. The savings can be reinvested in other services and new treatments.3
Crohn's & Colitis UK lists several reasons your team might suggest changing brand: a cheaper version that works just as well, a shortage of your current brand, a manufacturer stopping production, or a different device or formulation that might suit you better.12
Is it safe to switch brand?
NHS England quotes the UK medicines regulator, the MHRA, which says a licensed biosimilar is interchangeable with its original and with other biosimilars of the same medicine. A prescriber can expect the same effect from either, and switching between them has become acceptable clinical practice.3
Crohn's & Colitis UK says there is no evidence that switching to a biosimilar makes Crohn's or colitis worse or causes a flare. It also says you should be told before a switch, whether by letter, text, email or at an appointment, and have a chance to discuss it so the decision takes your needs and preferences into account.2
What might feel different after a switch?
The medicine itself should work the same way, but Crohn's & Colitis UK lists some practical differences you may notice:25
- A different injection device, such as a pen instead of a syringe, a different needle size or a different way of triggering the injection. Your nurse should show you how to use it.
- A different homecare company delivering your medicine.
- How long the medicine can be kept out of the fridge, which matters for travel.
- Slightly different inactive ingredients. Some brands leave out ingredients to make injections less painful, while others may not suit people with certain allergies.
- Side effects: the risk of side effects is no higher with a biosimilar than with the original brand. But brands are not identical, so some people notice different side effects after a switch.25
If you have any problems after switching, tell your IBD team. Crohn's & Colitis UK says that, depending on what happens, they may suggest going back to your original brand or trying a different medicine.2
Questions you could ask your IBD team
Sources
This article is written in our own words from these sources. Each number in the text points to one of them.
- Crohn's & Colitis UK Understanding medicines for Crohn's and Colitis Read on the Crohn's & Colitis UK website: Understanding medicines for Crohn's and Colitis
- Crohn's & Colitis UK Biologic medicines and other targeted treatments Guide, Jul 2023 Read on the Crohn's & Colitis UK website: Biologic medicines and other targeted treatments
- NHS England Biosimilar medicines Read on the NHS website: Biosimilar medicines
- Crohn's & Colitis UK Infliximab Guide, Jun 2024 Read on the Crohn's & Colitis UK website: Infliximab
- Crohn's & Colitis UK Adalimumab Guide, Sep 2024 Read on the Crohn's & Colitis UK website: Adalimumab
- Crohn's & Colitis UK Ustekinumab Read on the Crohn's & Colitis UK website: Ustekinumab
- Cochrane (via PMC) Infliximab for medical induction of remission in Crohn's disease Systematic review, Nov 2023 Read the review: Infliximab for medical induction of remission in Crohn's disease
- NICE Infliximab and adalimumab for the treatment of Crohn's disease (TA187) Guideline, May 2010 Read on the NICE website: Infliximab and adalimumab for the treatment of Crohn's disease (TA187)